Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
2000 1
2009 3
2011 2
2012 2
2013 1
2014 1
2017 1
2019 1
2020 4
2021 2
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %, %
The following terms were not found in PubMed: 20JN, 5BAuthor
Page 1
Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States.
Lai Y, Bensimon AG, Gao E, Bhattacharya R, Xu R, Chevure J, Imai K, Haas NB. Lai Y, et al. Clin Genitourin Cancer. 2023 Oct;21(5):612.e1-612.e11. doi: 10.1016/j.clgc.2023.03.016. Epub 2023 Apr 6. Clin Genitourin Cancer. 2023. PMID: 37137809 Free article.
Costs of adjuvant and subsequent treatments, adverse events, disease management, and terminal care were estimated in 2022 US$. Utilities were based on EQ-5D-5L data collected in KEYNOTE-564. Outcomes included costs, life-years (LYs), and quality-adjusted LYs (QALYs). ...
Costs of adjuvant and subsequent treatments, adverse events, disease management, and terminal care were estimated in 2022 US$. Utilities wer …
Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial.
McGregor B, O'Donnell PH, Balar A, Petrylak D, Rosenberg J, Yu EY, Quinn DI, Heath EI, Campbell M, Hepp Z, McKay C, Steinberg J, Regnault A, Mazerolle F, Galsky MD. McGregor B, et al. Eur Urol. 2022 May;81(5):515-522. doi: 10.1016/j.eururo.2022.01.032. Epub 2022 Feb 12. Eur Urol. 2022. PMID: 35168844 Free PMC article. Clinical Trial.
DESIGN, SETTING, AND PARTICIPANTS: Enrolled patients with LA/mUC who received EV were invited to electronically complete two HRQoL instruments (EORTC QLQ-C30 and EQ-5D-3L) at baseline and day 1 of each cycle until treatment discontinuation. ...Pain was lower at cycle 3 tha …
DESIGN, SETTING, AND PARTICIPANTS: Enrolled patients with LA/mUC who received EV were invited to electronically complete two HRQoL instrumen …
Mapping MOS-HIV to HUI3 and EQ-5D-3L in Patients With HIV.
Joyce VR, Sun H, Barnett PG, Bansback N, Griffin SC, Bayoumi AM, Anis AH, Sculpher M, Cameron W, Brown ST, Holodniy M, Owens DK. Joyce VR, et al. MDM Policy Pract. 2017 Jul 3;2(2):2381468317716440. doi: 10.1177/2381468317716440. eCollection 2017 Jul-Dec. MDM Policy Pract. 2017. PMID: 30288427 Free PMC article.
Data from the first trial (n = 367) formed the estimation data set for the HUI3 (4,610 observations) and EQ-5D-3L (4,662 observations) mapping algorithms; data from the second trial (n = 168) formed the HUI3 (1,135 observations) and EQ-5D-3L (1,152 observations) ext …
Data from the first trial (n = 367) formed the estimation data set for the HUI3 (4,610 observations) and EQ-5D-3L (4,662 observations …
Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease.
Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, Yu W, Sundaram V, Holodniy M, Brown ST, Cameron W, Youle M, Sculpher M, Anis AH, Owens DK. Joyce VR, et al. J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):27-36. doi: 10.1097/QAI.0b013e31818ce6f3. J Acquir Immune Defic Syndr. 2009. PMID: 19295332 Clinical Trial.
MEASUREMENTS: Baseline sociodemographic and clinical indicators and baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HIV), the EQ-5D, the EQ-5D visual analog scale (EQ-5D VAS), the Health Utilities Index Mark 3 (HUI3), and standard gamble …
MEASUREMENTS: Baseline sociodemographic and clinical indicators and baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HI …
Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial.
Hammond NE, Finfer SR, Li Q, Taylor C, Cohen J, Arabi Y, Bellomo R, Billot L, Harward M, Joyce C, McArthur C, Myburgh J, Perner A, Rajbhandari D, Rhodes A, Thompson K, Webb S, Venkatesh B; ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Hammond NE, et al. Intensive Care Med. 2020 Sep;46(9):1696-1706. doi: 10.1007/s00134-020-06169-1. Epub 2020 Jul 16. Intensive Care Med. 2020. PMID: 32676679
Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. ...Bacteraemia was not associated with worse HRQoL in any domains of the E …
Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D- …
Associations between social networks, cognitive function, and quality of life among older adults in long-term care.
Dodds L, Brayne C, Siette J. Dodds L, et al. BMC Geriatr. 2024 Mar 4;24(1):221. doi: 10.1186/s12877-024-04794-9. BMC Geriatr. 2024. PMID: 38438951 Free PMC article.
Residents were given a battery of assessments measuring social network structure (Lubben Social Network Scale, LSNS-12), quality of life (EuroQol 5D, Eq. 5D5L) and cognitive function (Montreal Cognitive Assessment, MoCA). ...
Residents were given a battery of assessments measuring social network structure (Lubben Social Network Scale, LSNS-12), quality of life (Eu …
Systematic review of 29 self-report instruments for assessing quality of life in older adults receiving aged care services.
Siette J, Knaggs GT, Zurynski Y, Ratcliffe J, Dodds L, Westbrook J. Siette J, et al. BMJ Open. 2021 Nov 18;11(11):e050892. doi: 10.1136/bmjopen-2021-050892. BMJ Open. 2021. PMID: 34794991 Free PMC article.
The period between 1990 and 2000 produced the greatest number of newly developed instruments. The EuroQoL-5 Dimensions (EQ-5D) and Short Form-series were used across multiple aged care contexts including home and residential care. More recent instruments (eg, ICEpop CAPabi …
The period between 1990 and 2000 produced the greatest number of newly developed instruments. The EuroQoL-5 Dimensions (EQ-5D) and Sh …
A cost-effectiveness analysis of dialectical behaviour therapy for treating individuals with borderline personality disorder in the community.
Murphy A, Bourke J, Flynn D, Kells M, Joyce M. Murphy A, et al. Ir J Med Sci. 2020 May;189(2):415-423. doi: 10.1007/s11845-019-02091-8. Epub 2019 Sep 3. Ir J Med Sci. 2020. PMID: 31482522
Direct health resources were included and effectiveness was measured using the EQ-5D-5L questionnaire. To examine cost-effectiveness, incremental costs are compared with incremental quality-adjusted life years, to estimate an incremental cost-effectiveness ratio. ...
Direct health resources were included and effectiveness was measured using the EQ-5D-5L questionnaire. To examine cost-effectiveness, …
21 results